Utilizing the strength of our own Immune system to fight cancers is proving to be very successful approach.
- Immuno-oncology (I/O) is emerging as one of the key areas in oncology drug discovery and development.
- L2P Research® offers more than 30 syngeneic cancer models to be used in immune competent mice.
- We have fully validated tumor lines ready to be implanted for your next I/O study.
- Our Syngeneic tumor models have been published in prestigious journals like “Cell” and “Cancer Research”.
- For several of our models, we have growth curves available, and we continue to build our data with therapeutic antibodies like anti-CTLA-4, anti-PDL-1, and anti-PD-1.
- Our I/O models include cancers specific to Colon, Brain, Lung, Skin, Liver, Pancreas, Kidney and ovaries.
- We also provide tumors/spleens and peripheral blood from our Syngeneic models, to optimize your FACS analysis.
Validated syngeneic Models
|
|
|
Cell line
|
Mice Strain
|
Tissue type
|
| MC38/ MC-38 LUC/MC38-hPD1/PDL1 |
C57BL/6 |
Colon |
| Panc-02 / Panc-02-LUC |
C57BL/6 |
Pancreas |
| LL/2 |
C57BL/6 |
Lung |
| 3LL |
C57BL/6 |
Lung |
| EG7.OVA |
C57BL/6 |
Lymphocyte |
| EMT-6 |
BALB/C |
Breast |
| 4T1 / 4T1-LUC |
BALB/C |
Breast |
| ID8 |
C57-Albino |
Ovarian |
| ID8-LUC |
C57 -Albino |
Ovarian |
| Renca |
BALB/C |
Kidney |
| Renca-LUC |
BALB/C |
Kidney |
| M-109 (Madison -109) |
BALB/C |
Lung |
| CT26 |
BALB/C |
Colon |
| B16F10 |
C57BL/6 |
Melanoma |
| Raji-B |
NSG-CD34+/Humanized |
Lymphocyte |
| OVCAR-3 |
NSG-CD34+/Humanized |
Ovarian |
| TUBO |
BALB/C |
Breast |
| MMTV-PyMT TG (Spontaneous) |
FVB / C57BL6 |
Breast |
| E0771 (CRL-3461) |
C57BL/6 |
Breast |
| KRASG12D/P53R172H/Pancreatic CRE |
FVB /C57BL/6 |
Pancreas |
*Please contact us for more Information
